Next-Generation Sequencing (NGS) is the dominating technology segment. Its leadership is attributed to its unmatched sensitivity and ability to detect extremely low levels of residual cancer cells by interrogating thousands of genetic markers simultaneously, making it the preferred choice for precision oncology and clinical trials.
While NGS leads in sensitivity, PCR remains a critical segment due to its cost-efficiency, faster turnaround times, and accessibility for routine hospital-scale testing. Innovations such as digital droplet PCR (ddPCR) are further enhancing its sensitivity, making it a vital tool in resource-constrained settings and decentralized laboratory networks.
Haematological malignancies, including leukaemia, lymphoma, and multiple myeloma, are the leading segments. MRD testing has become a gold standard for these cancers to guide treatment intensification or de-escalation. However, there is also significant emerging growth in the application of MRD testing for solid tumors.
North America is the leading market due to its advanced oncology infrastructure, favorable reimbursement frameworks (such as coverage for Natera’s Signatera and Adaptive’s clonoSEQ), and the high concentration of leading biotech innovators and clinical trials.
Growth is primarily driven by the transition toward personalized medicine, the increasing prevalence of blood cancers, expanding regulatory approvals, and the inclusion of MRD endpoints in pharmaceutical clinical trials to substantiate treatment effectiveness and accelerate drug approvals.
AI and machine learning are being integrated into bioinformatics pipelines to improve data interpretation. These technologies help automate variant calling, minimize human error, and provide real-time analysis, which is essential for scaling MRD testing in clinical routines.
The market faces hurdles such as high capital costs for NGS platforms, a lack of universal standardization across different testing methodologies, complex bioinformatics requirements, and limited infrastructure/reimbursement in developing economies.
Recent milestones include Natera Inc. and Adaptive Biotechnologies securing expanded reimbursement coverage for their respective assays, Roche entering strategic agreements for decentralized PCR solutions in Europe, and Thermo Fisher Scientific launching advanced NGS platforms with automated workflows to speed up clinical uptake.
Significant opportunities lie in the development of MRD-guided therapies, expansion into the Asia-Pacific region (the fastest-growing market due to rising cancer prevalence), and strategic partnerships between pharmaceutical companies and diagnostic developers to validate tests for commercial use.
